Claims for Patent: 8,557,256

Summary for Patent: 8,557,256

Title:	Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
Abstract:	A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Inventor(s):	Aoki; Kei Roger (Coto De Caza, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (San Mateo, CA), Leon; Judith M. (San Juan Capistrano, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/460,898
Patent Claims:	1. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component of a Botulinum toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 2. The method of claim 1, wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 3. The method of claim 1, wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days. 4. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from a single Botulinum toxin type to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons, and wherein said Botulinum toxin is Botulinum toxin type B. 5. A method for treating cervical dystonia, the method comprising the step of administering to a human patient a therapeutically effective amount of a neurotoxic component from only a Botulinum toxin type B to thereby treat the patient's cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 6. The method of claim 1, wherein between about 80 units and about 460 units of the neurotoxic component is administered. 7. The method of claim 1, wherein the neurotoxic component is administered by intramuscular injection. 8. The method of claim 1, wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component. 9. The method of claim 4, wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 10. The method of claim 4, wherein between about 80 units and about 460 units of the neurotoxic component is administered. 11. The method of claim 4, wherein the neurotoxic component is administered by intramuscular injection. 12. The method of claim 4, wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days. 13. The method of claim 4, wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component. 14. The method of claim 5, wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 15. The method of claim 5, wherein between about 80 units and about 460 units of the neurotoxic component is administered. 16. The method of claim 5, wherein the neurotoxic component is administered by intramuscular injection. 17. The method of claim 5, wherein alleviation of the cervical dystonia occurs in about 3 to about 7 days. 18. The method of claim 5, wherein an alleviation of a symptom of the cervical dystonia is evident 3 to 7 days after the administration of the neurotoxic component. 19. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a Botulinum toxin type B, thereby reducing the severity of an abnormal head position symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 20. The method of claim 19, wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 21. The method of claim 19, wherein between about 80 units and about 460 units of the neurotoxic component is administered. 22. The method of claim 19, wherein the neurotoxic component is administered by intramuscular injection. 23. The method of claim 19, wherein said severity is reduced in about 3 to about 7 days. 24. The method of claim 19, wherein reduction in said severity is evident 3 to 7 days after the administration of the neurotoxic component. 25. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of a neurotoxic component of a Botulinum toxin type B, thereby reducing a neck pain symptom of cervical dystonia, wherein the neurotoxic component administered to the patient has a molecular weight of about 150 kilodaltons. 26. The method of claim 25, wherein between about 100 units and about 1000 units of the neurotoxic component is administered. 27. The method of claim 25, wherein between about 80 units and about 460 units of the neurotoxic component is administered. 28. The method of claim 25, wherein the neurotoxic component is administered by intramuscular injection. 29. The method of claim 25, wherein said symptom is reduced in about 3 to about 7 days. 30. The method of claim 25, wherein reduction in said symptom is evident 3 to 7 days after the administration of the neurotoxic component.

Details for Patent 8,557,256

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2013-12-28